Applied Evidence

Migraine: Expanding our Tx arsenal

Author and Disclosure Information

 

References

Butterbur, in particular, has been found to be beneficial for migraine prevention in 2 small placebo-controlled trials. In a randomized controlled study of 245 patients P hybridus, (specifically, the German formulation, Petadolex), 75 mg BID, reduced the frequency of migraine attack by 48% at 4 months, compared to placebo (number needed to treat, 5.3).44 No difference was found at lower dosages. The most common reported adverse effect was burping.

Regrettably, unpurified butterbur extract contains pyrrolizidine alkaloids, potentially hepatotoxic and carcinogenic compounds. Because of variations in purification in production facilities in the United States, butterbur supplements might not have all of these compounds removed—and so should be used with caution.41

Magnesium. Studies evaluating the use of magnesium have demonstrated varied results; differences in methods and dosing have limited broad application of findings. As with most supplements considered for prophylactic treatment, magnesium dosing is poorly understood, and bioavailability varies in its different forms. Oral supplementation can be given as magnesium dicitrate, 600 mg/d.45

Recently, products containing various combinations of feverfew, coenzyme Q10, riboflavin, magnesium, and other supplements have shown benefit in early clinical trials.36,37

Neural stimulation. Over the past few years, a variety of transcutaneous nerve stimulator devices have gained FDA approval for use in migraine prophylaxis. The long-term safety and efficacy of these devices is not yet well understood, but they appear to provide headache relief in the short term and decrease the frequency of headache.38 Use of the noninvasive stimulators is limited today by high cost and poor coverage by US health care insurers.

Continue to: Newly available medical therapy

Pages

Recommended Reading

Active migraine in women linked to lower risk of developing T2DM
Journal of Clinical Outcomes Management
Can higher MAP post cardiac arrest improve neurologic outcomes?
Journal of Clinical Outcomes Management
Can lifestyle modifications delay or prevent Alzheimer’s disease?
Journal of Clinical Outcomes Management
Cerebral small vessel disease progression linked to MCI in hypertensive patients
Journal of Clinical Outcomes Management
Researchers exploring ways to mitigate aging’s impact on diabetes
Journal of Clinical Outcomes Management
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
Journal of Clinical Outcomes Management
Population-level rate of SUDEP may have decreased
Journal of Clinical Outcomes Management
DMTs, stem cell transplants both reduce disease progression in MS
Journal of Clinical Outcomes Management
Obesity paradox applies to post-stroke mortality
Journal of Clinical Outcomes Management
How seizure prediction may benefit patients with epilepsy
Journal of Clinical Outcomes Management